Page 3 - Protein Engineering News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The global protein engineering market size is estimated to reach around USD 15.25 billion by 2032, increasing from USD 3.18 billion in 2022, According to...

Current information from the Federal Administration. All press releases from the Federal Administration, the departments and offices.

Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development candidate for each program

<p><strong>Karl Klose</strong>, director of The South Texas Center for Emerging Infectious Diseases (STCEID) and the Robert J. Kleberg, Jr. and Helen C. Kleberg College of Sciences Endowed Professor, coauthored a research article with&nbsp;<strong>Cameron Lloyd&nbsp;</strong>&rsquo;23, a UTSA doctoral student who graduated in August with a Ph.D. in molecular microbiology and immunology under the guidance of Klose.&nbsp;</p> <p>According to the&nbsp;<a href="https://www.cdc.gov/cholera/infection-sources.html">Centers ...

Karl Klose, director of The South Texas Center for Emerging Infectious Diseases (STCEID) and the Robert J. Kleberg, Jr. and Helen C. Kleberg College of Sciences Endowed Professor, coauthored a research article with Cameron Lloyd '23, a UTSA doctoral student who graduated in August with a Ph.D. in molecular microbiology and immunology under the guidance of Klose.